Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division; Agency for Science, Technology and Research (A*STAR) - Singapore Immunology Network (SIgN)
Prior immunological exposure to dengue virus can be both protective and disease-enhancing during subsequent infections with different dengue virus serotypes. We provide here for the first time a systematic, longitudinal analysis of B cell, T cell, and antibody responses in the same patients. Antibody responses as well as T and B cell activation differentiated primary versus secondary responses. Disease severity was associated with lower frequencies of activated, terminally differentiated T cells and higher percentages of effector memory CD4 T cells. Patients with more severe disease tended to have higher percentages of plasmablasts. This did not translate into long-term antibody titers, since neutralizing titers after six months were associated with percentages of specific memory B cells but not with acute plasmablast activation. Overall, our unbiased analysis reveals novel and unexpected associations between cellular profiles and disease severity,opening new opportunities to study immunopathology in dengue disease and potential predictive value of these parameters.
Keywords: Dengue, T cell, B cell, Longitudinal, Disease Severity, Antibodies, Correlates of Protection
Rouers, Angeline and Chng, Melissa and Lee, Bernett and Rajapakse, Menaka P. and Kaur, Kaval and Toh, Ying Xiu and Sathiakumar, Durgalakshmi and Leo, Yee Sin and Vora, Kalpit and Casimiro, Danilo and Lim, Bing and Tucker-Kellogg, Lisa and Rivino, Laura and Newell, Evan W. and Fink, Katja, Immune Cell Phenotypes that Determine Disease Severity and Long-Term Neutralizing Antibody Titers after Natural Dengue Virus Infection. Available at SSRN: https://ssrn.com/abstract=3565008 or http://dx.doi.org/10.2139/ssrn.3565008
This version of the paper has not been formally peer reviewed.
Subscribe to this free journal for more curated articles on this topic
FOLLOWERS
16
PAPERS
7,988
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.